1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Authors

Showing 4 results for author "Elias Jabbour".

$Thumbnail for Improving Efficacy and Safety Outcomes in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Morphologic Remission Treated With Obecabtagene Autoleucel$

ALL - 1125

Improving Efficacy and Safety Outcomes in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Morphologic Remission Treated With Obecabtagene Autoleucel

Elias Jabbour

Poster Presenter: Elias Jabbour

Video

Thumbnail for Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

ALL - 589

Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

Elias Jabbour

SOHO 2026 Annual Meeting

Authors

Improving Efficacy and Safety Outcomes in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Morphologic Remission Treated With Obecabtagene Autoleucel

Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

Clinical Outcomes in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R B-ALL) Who Achieved Remission Following Treatment with Obecabtagene autoleucel (obe-cel) in the FELIX Study

Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations